NEW YORK (GenomeWeb News) – Microlytic, a Copenhagen, Denmark-based protein crystallization tools firm, announced today that it has raised $3.5 million in venture capital funding.
The firm, which also has operations in Boston, plans to use the funds to expand sales and production of products for the structural biology market. It makes the Crystal Former device for crystallizing proteins and MCSG Screens, a set of crystallization reagents.
Funding was provided by Danish investment firms CAT Science Park and Vaekstfonden.
Jesper Roested, investment director of Vaekstfonden, has been named chairman of the board of Microlytic.